Share Name Share Symbol Market Type Share ISIN Share Description
Puretech Health LSE:PRTC London Ordinary Share GB00BY2Z0H74 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25p -0.19% 134.50p 134.00p 135.00p 138.00p 138.00p 138.00p 11,603 16:35:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 3.6 -67.4 -17.0 - 319.34

Puretech Share Discussion Threads

Showing 101 to 124 of 125 messages
Chat Pages: 5  4  3  2  1
DateSubjectAuthorDiscuss
04/9/2017
11:16
also motley fool said similar to ic.
edwardt
04/9/2017
07:36
Thanks Rabutan for the heads up on IC. Good to see Bharatt Chowrira continuing to fill his boots at 139p.
poppa wobbler
02/9/2017
18:25
Gets a results write up in IC, bit too cheap they say and give it a Buy.
rambutan2
02/9/2017
13:51
Yes, lots happening, cash ok for at least another year, and Gelesis and Akili trial results nearing. If the former can kick us off with a positive then that would be perfect. If not, well a few weeks to lick our wounds and then hopefully Akili will save the day... htTP://puretechhealth.com/images/investors/20180830_prtc_2017-half_year_report.pdf
rambutan2
30/8/2017
08:49
reads well to me. cash burn under control!
edwardt
24/8/2017
10:17
any views on what we should expect at interims? extent of cash burn??
edwardt
25/7/2017
16:51
got what I wanted. now will do precisely nothing with this for the next 10 years. (that is possibly a lie but my intention is honourable!).
edwardt
12/7/2017
12:43
Getting there: PureTech Health plc ("PureTech", LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that Gelesis, Inc. (a subsidiary of PureTech Health) has completed treatment of the final patient in the pivotal GLOW (Gelesis Loss Of Weight) Study. GLOW was designed to assess the long-term efficacy and safety of lead product candidate Gelesis100 over a six-month period across a broad patient population. Results from this registration-enabling trial are anticipated in Q3 2017. Gelesis has also enrolled its first European patient in the ongoing LIGHT-UP study with its second product candidate, Gelesis200, for weight loss and glycaemic control. LIGHT-UP will enrol individuals across the United States, Canada, and Europe who are overweight or have obesity and also have prediabetes or metformin-treated type 2 diabetes. Dr. Bharatt Chowrira, President and Chief of Business and Strategy at PureTech Health, said: "We're delighted to have achieved these important milestones and to expand the breadth of the Gelesis platform. As a result of new, preclinical research and the pioneering work of Gelesis in this emerging field of mechanobiology, we are also planning or initiating pilot studies across a number of additional indications including early nonalcoholic steatohepatitis (NASH), inflammatory bowel disease (IBD), and other gastrointestinal disorders." http://uk.advfn.com/stock-market/london/puretech-PRTC/share-news/PureTech-Health-PLC-PRTCs-Gelesis-Notes-Last-Patie/75218542
rambutan2
06/7/2017
23:10
Surely Bharatt has bought some more?!
lendmeafiver
06/7/2017
14:41
No immediate slip back today, i'm happy to see.
rambutan2
05/7/2017
19:26
Maybe, but all seems to be triggered by a series of relatively small purchases after 2pm today
lendmeafiver
05/7/2017
19:20
Perhaps news of trial result imminent? Both Gelesis and Akili were on the recent below presentation as being due 1st half 2017: htTP://www.jefferies.com/CMSFiles/Jefferies.com/files/Conferences/060716/Presentations/PureTech%20Health%20plc.pdf
rambutan2
05/7/2017
17:38
probably will pull back tomorrow. fear of missing out is not a good reason to buy near term. I will sit on my hands before buying but I do want to buy having read Jeffries note...
edwardt
05/7/2017
16:40
That was some jump in share price on zero newsflow, back to the IPO price by the end of the week?!
lendmeafiver
05/7/2017
15:31
Bharatt buying again?
lendmeafiver
03/7/2017
16:12
So it's essentially if you don't want your PRTC Shares then Bharatt Chowrira will buy them from you!
lendmeafiver
01/7/2017
02:32
Gelesis 100 trial results are also on the horizon.
rambutan2
30/6/2017
20:14
Another another tick up last thing today
lendmeafiver
29/6/2017
15:02
Share price has ticked up ever so slightly also, not sure if it's anything to do with that news or Chowrira's continuous buying of stock or a combination of them both.
lendmeafiver
29/6/2017
11:41
BOSTON and SAN FRANCISCO, June 28, 2017 - Akili Interactive Labs, Inc. ("Akili") today announced the appointment of former Cubist Pharmaceuticals CEO, Robert J. Perez, as Executive Chairman. Mr. Perez has been a commercial advisor with the company for the past year and will now be joining in the more official leadership role as the company continues its growth. Additionally, the company has added former DreamWorks Interactive CEO, Glenn Entis, and former Chief Game Designer at Google, Noah Falstein, as Executive Advisors. These three biotech and game industry veterans will bring their cross-disciplinary expertise to the Akili team as the company advances its diverse product portfolio and prepares for the potential commercialization of Akili's lead product, Project:EVO(TM) . The Project:EVO(TM) platform is currently being evaluated in a pivotal, registration-enabling trial in patients with paediatric ADHD, which is expected to read out in the second half of 2017. http://uk.advfn.com/stock-market/london/puretech-PRTC/share-news/PureTech-Health-PLC-PRTCs-Akili-Names-Former-Cubis/75130350
rambutan2
09/6/2017
14:11
Is worth remembering that PRTC offers effectively 100% $US exposure.
rambutan2
09/6/2017
14:08
Jefferies webcast now available: htTP://puretechhealth.com/investors-reports-presentations.php
rambutan2
01/6/2017
14:28
I sat through the Webcast of the investor meeting in London last month, he pitched in at the end, exit strategy, sounded good, clearly a highly experienced sector chap.
lendmeafiver
01/6/2017
12:43
Agree. And as chance would have it, there's an opportunity to listen to him present a week today: PureTech Health to Present at Jefferies 2017 Global Healthcare Conference PureTech Health plc ("PureTech", LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, today announced that Bharatt Chowrira, President and Chief of Business and Strategy at PureTech Health, will present at the Jefferies 2017 Global Healthcare Conference in New York City on Thursday, 8 June, at 9.30AM EDT. A webcast of the presentation will be available at hTTp://puretechhealth.com/investors.php under the Reports and Presentations tab.
rambutan2
Chat Pages: 5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20170919 18:59:45